Regulatory & Policy

Organogenesis advances first amniotic tissue biologic to FDA review for knee osteoarthritis

Edited by Robert McTiernan··3 min read
Organogenesis advances first amniotic tissue biologic to FDA review for knee osteoarthritis

The US FDA's acceptance of a Biologics License Application (BLA) for Amnuvx (azimplacel, formerly Renu) — a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis — arrives at a moment when multiple late-stage regenerative and disease-modifying therapies advance through clinical development as the knee OA therapeutic field experiences its most concentrated late-stage regulatory activity in decades. Massachusetts-based Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the filing acceptance on July 6, 2026, with the FDA assigning a PDUFA target action date of April 24, 2027.

The BLA, submitted via a rolling process that began in December 2025 with non-clinical modules and was completed in April 2026 with clinical and chemistry, manufacturing, and controls data, seeks approval for Amnuvx as a treatment for pain in adults with symptomatic knee osteoarthritis. No priority review designation was reported. The product previously held FDA Regenerative Medicine Advanced Therapy (RMAT) designation for knee OA, granted in 2021, and was commercially available for approximately six years under Section 361 of the Public Health Service Act before the formal BLA pathway became necessary following regulatory changes governing human cells, tissues, and cellular and tissue-based products.

The submission is supported by two Phase III randomized trials together with the product's prior commercial experience under Section 361. Organogenesis used a rolling BLA process beginning in December 2025 after FDA feedback at a Type B meeting supported the proposed development package.

Amnuvx comprises cryopreserved amniotic fluid cells and micronized amniotic membrane intended to provide anti-inflammatory, immunomodulatory and regenerative effects following intra-articular injection. The product's activity is characterized as broadly anti-inflammatory, immunomodulatory, and potentially regenerative, mediated through the biological constituents of amniotic tissue.

The AllSci BriefSystematic R&D and deal news. Daily.

There is a growing class of tissue-derived biologics seeking regulatory approval for musculoskeletal indications, a field where no FDA-approved biologic or regenerative therapy has previously cleared the threshold specifically for knee OA pain management. San Diego-based Biosplice Therapeutics submitted an NDA in January 2026 for lorecivivint, a CLK/DYRK kinase inhibitor delivered by intra-articular injection, seeking approval as both a symptomatic and potentially disease-modifying therapy for knee OA — the first submission to include joint space width data as evidence of structural benefit. South Korea-based MEDIPOST's Cartistem, an allogeneic umbilical cord blood-derived mesenchymal stem cell therapy, met all primary and secondary endpoints in a Japan Phase III trial in May 2026 and is preparing a biologics license application in that market, while its US subsidiary is advancing toward a Phase III IND. Doron Therapeutics holds RMAT and Fast Track designations for MOTYS (PTP-001), a placental tissue-derived biologic in Phase III development for knee OA, while Kolon TissueGene's TG-C, a cell and gene therapy, has completed patient dosing in two US Phase III trials and is preparing a BLA submission expected in 2027. Multiple modalities—including amniotic allografts, stem cell therapies, kinase inhibitors and cell and gene therapies—are now advancing toward regulatory review in knee OA. That marks a significant shift after decades in which treatment largely relied on NSAIDs, corticosteroids and hyaluronic acid injections.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article